MDxHealth

Kempen is pleased to announce the successful EUR 36m capital increase via accelerated bookbuild by MDxHealth

• The capital increase comprised of 9,989,881 new shares, representing 20% of MDxHealth’s pre-deal outstanding share capital, at an issue price of EUR 3.60 per share, resulting in gross proceeds of EUR 36 million
• The Company’s existing long-term shareholders Biovest and Valiance indicated their support of the transaction ahead at the launch of the capital increase and participated in the share offering
• The pre-launch market sounding exercise and accelerated book-building process generated strong demand from Belgian, Dutch and international Life Science specialist investors 
• Transaction proceeds are envisaged to be used to grow the business by facilitating adoption of the Company's commercial tests with urologists and payors in the US and Europe, studies and tests for (a) expanding the clinical indications for SelectMDx, (b) supporting the further commercial roll-out of AssureMDx and (c) launching InformMDx, expand usability of the Company’s tests by porting them onto IVD sample-to-answer platforms (POC) and further investments in the product pipeline

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of urological cancer. The Company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California